Rodney Falk, MD
Enriched profileDirector of the Cardiac Amyloidosis Program and Associate Professor of Medicine at Harvard Medical School · Brigham and Women's Hospital
Rodney Falk is Director of the Cardiac Amyloidosis Program and Associate Professor of Medicine at Harvard Medical School at Brigham and Women's Hospital. OpenAlex indexes 451 publications with 27,762 citations (h-index 89); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Cardiovascular Disease profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Rodney Falk, MD, is Director of the Cardiac Amyloidosis Program and Associate Professor of Medicine at Harvard Medical School at Brigham and Women's Hospital. The public record shows 451 publications with 27,762 citations (h-index 89), centered on Amyloidosis: Diagnosis, Treatment, Outcomes, Cardiac tumors and thrombi, Cardiac electrophysiology and arrhythmias. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 6 companies, 2 NIH-funded awards (1986–2019).
- Most recent indexed publication: 2026 · Circulation. Heart failure
- Top research focus: Amyloidosis: Diagnosis, Treatment, Outcomes
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 203.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Cardiovascular Disease
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗ - Internal Medicine
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Brigham and Women's Watkins Cardiovascular Clinic, 70 Francis Street, Boston, MA 02115
Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- ION-682884 in Patients With TTR Amyloid Cardiomyopathy
Sponsor: Brigham and Women's Hospital
- 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
Sponsor: Brigham and Women's Hospital
- Molecular Imaging of Primary Amyloid Cardiomyopathy
Sponsor: Brigham and Women's Hospital
Industry payments
Updated 18 Oct 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202514 payments$38,422openpaymentsdata.cms.gov ↗
- BridgeBio Pharma, Inc.Program year20252 payments$13,125openpaymentsdata.cms.gov ↗
- Alexion Pharmaceuticals, Inc.Program year20253 payments
NIH funding
Updated 18 Oct 2026
2 NIH research awards on record, funded 1986–2019 per NIH RePORTER. The latest:
- Molecular Imaging of Primary Amyloid Cardiomyopathy
Brigham and Women'S Hospital
FY2019$801,025R01HL130563 - Molecular Imaging of Primary Amyloid Cardiomyopathy
Brigham and Women'S Hospital
FY2018$801,025R01HL130563 - Molecular Imaging of Primary Amyloid Cardiomyopathy
Brigham and Women'S Hospital
FY2017$823,259R01HL130563
Congress activity
Updated 18 Oct 2026
3 congress contributions (2019–2024) across ASH per OpenAlex. The most recent:
- Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis
ASH Annual Meeting
ASH2024Co-author - The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis
ASH Annual Meeting
ASH2020Co-author - Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
ASH Annual Meeting
ASH2019Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.
Circulation. Heart failure
Clinical Trial2026 - Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging.
European heart journal. Cardiovascular Imaging
Review2026 - Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis.
European heart journal. Cardiovascular Imaging
Article2022 - Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.
European heart journal
Article2022
Most-cited works
by citation count (OpenAlex)- 01Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisArticle2,085 citations2016
- 02
- 03The Systemic AmyloidosesArticle1,182 citations1997
- 04Diagnosis and Management of the Cardiac AmyloidosesArticle791 citations2005
- 05AL (Light-Chain) Cardiac AmyloidosisArticle650 citations2016
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
radcliffecardiology.com/authors/rodney-falk
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →radcliffecardiology.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
Editorial & leadership roles
journal and society appointments- Course Director
New Horizons in Amyloidosis
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →radcliffecardiology.com ↗
Secondary affiliations
appointments beyond the home institution- Scientific Advisor
Amyloidosis Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →amyloidosis.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
Marc Sabatine, MD
Brigham and Women's Hospital
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens